Skip to main content
GeroScience logoLink to GeroScience
. 2026 Mar 17;48(3):3821–3830. doi: 10.1007/s11357-026-02201-2

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice

Ron Korstanje 1,✉, Randy Strong 2, Adam B Salmon 3, Molly A Bogue 1, Sean P Curran 4, Vivian Diaz 2, Elizabeth Fernandez 2, Brett Ginsburg 5, Melissa Han 6, David E Harrison 1, Catherine Kaczorowski 7, Matt Kaeberlein 8, Brian K Kennedy 9, Navasuja Kumar 10, Michael LaCroix-Fralish 11, Scott F Leiser 12, James F Nelson 13, Michael Polymenis 14, Peter C Reifsnyder 1, Nadia A Rosenthal 1, Elena Silva 11, John Tower 15, Richard A Miller 6
PMCID: PMC13356140  PMID: 41843349

Abstract

The Interventions Testing Program (ITP) evaluated eleven compounds in genetically heterogeneous UM-HET3 mice to assess their potential to extend lifespan. These interventions included both novel agents and previously tested compounds administered at novel doses or starting ages. Despite prior evidence suggesting lifespan benefits of these proposed interventions in other models or under different conditions, none of the tested compounds significantly increased lifespan in male or female mice. Notably, astaxanthin, mitoglitazone, and meclizine—previously associated with lifespan extension in the ITP—showed no benefit when administered at different doses or starting at later ages. In females, astaxanthin, late-start mitoglitazone, and pioglitazone were associated with significantly reduced lifespan when pooling the data from all three sites. However, site-specific analysis revealed unusually long lifespans in control females at The Jackson Laboratory, prompting reanalysis using data from the other two sites and only showed a negative effect for mitoglitazone and pioglitazone. This study underscores the importance of rigorous, multi-site testing and highlights the challenges of translating promising initial findings into consistent lifespan benefits at other doses or with alternate starting ages. These results suggest that timing and dosage are critical variables in aging intervention studies and reinforce the need for cautious interpretation of single-site or single-cohort findings.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11357-026-02201-2.

Keywords: Interventions Testing Program, Lifespan extension, UM-HET3 mice, Aging interventions, Multi-site replication

Introduction

The National Institute on Aging’s Interventions Testing Program (ITP) investigates compounds that are hypothesized to extend lifespan by influencing fundamental aging processes or mitigating age-related diseases. The program is designed to address three central objectives: (1) to elucidate the biological mechanisms underlying aging; (2) to establish a robust preclinical framework for evaluating candidate interventions aimed at extending lifespan and improving healthspan; and (3) to assess the efficacy and safety of compounds currently available to consumers.

Candidate agents are nominated annually by the scientific community and undergo a rigorous two-stage peer review process. Selection is based on the strength of evidence supporting their potential to modulate aging-related processes and extend longevity. Results from all interventions, whether they are positive or negative findings, are published and publicly available.

A major strength of the program lies in its standardized and reproducible experimental design, which uses a genetically heterogeneous mouse model to enhance translational relevance. Studies are conducted in parallel at three independent sites: The Jackson Laboratory (TJL), the University of Michigan (UM), and the University of Texas Health Science Center at San Antonio (UT). Uniform protocols are applied across all sites, encompassing diet formulation and distribution, animal breeding, husbandry, and phenotypic monitoring.

For Cohort 2022 (C2022), the ITP tested eleven interventions. Several of these interventions used compounds not previously tested in the ITP, while others used compounds that have been tested before, but in the C2022 cohort were evaluated using a different concentration or starting time to see if they had similar (or better) effects.

Astaxanthin (Asta) is a naturally occurring xanthophyll carotenoid [1, 2] that is an efficient Nrf2 activator [3] with potent antioxidant activity [4] and broad health applications [5]. Astaxanthin (Asta) integrates into cellular membranes, spanning the lipid bilayer to enhance its stability and mitigate lipid peroxidation [6]. Its unique molecular structure enables efficient scavenging of free radicals both at the membrane surface and within its interior [7]. Additionally, Asta accumulates in mitochondria, where it provides protection against mitochondrial dysfunction [8, 9]. Our previous study used a target amount of 4000 ppm starting at 12 months of age and showed a 12% lifespan extension of median lifespan in males, without a significant effect on our index of late-life survival (a surrogate for ‘maximal’ lifespan) [10].

Meclizine (Mec) has been used as an antihistamine, anti-nausea, and anti-vertigo drug [11]. It binds mTOR and inhibits mTORC1 [12], which was the reason for testing in a previous UM-HET3 cohort where it showed an 8% increase in median lifespan for males starting at 12 months at a target amount of 800 ppm, without a significant effect on chance of survival to old age [10].

Mitoglitazone (also called M160) is a second generation PPARγ-sparing thiazolidinedione [13, 14]. Preclinical and clinical studies have shown that this compound, which has minimal affinity for PPARγ and works primarily by modulating the mitochondrial pyruvate carrier, mimics the insulin sensitizing pharmacology of pioglitazone without the liability of direct transcriptional activation. In our previous study, starting at 7 months of age, the compound extended median lifespan in males by 9% [15].

Similarly, pioglitazone (Pio) activates PPARγ [16]. It modulates the transcription of genes involved in the control of glucose and lipid metabolism in skeletal muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces the amount of glucose and glycated hemoglobin in the bloodstream [17], and is a widely prescribed medication for people with type 2 diabetes.

Alpha-ketoglutarate (AKG) is an intermediate involved in the tricarboxylic cycle. It is involved in multiple metabolic and cellular pathways including generating energy, producing new amino acids [18], transporting nitrogen [19], scavenging hydrogen peroxide [20], and regulating cellular signaling [21]. It was previously reported to extend lifespan in C.elegans [22], Drosophila [23], and C57BL/6 J mice [24]. In a previous study, the ITP did not find an increase in lifespan when starting AKG at 18 months of age [25].

Mifeprestone (Mife) is a synthetic steroid that antagonizes the activities of glucocorticoids and progesterone by binding to the type II glucocorticoid receptor and the progestin receptor. Mifepristone has significant positive effects on Drosophila lifespan in mated females with smaller but still significant positive effects in virgin females, and no effect in males [26]. Similarly, in C.elegans, mifepristone was found to increase the lifespan of mated hermaphrodite animals but had no effect in virgins [27]. In mice, mifepristone has been shown to have an anti-diabetic effect [28]; [29].

Atorvastatin is a statin that lowers cholesterol and triglycerides in the blood. Telmisartan is an angiotensin II receptor blocker (ARB). The combination of a statin with an ARB has been associated with modulation of alpha-Klotho and a previous study using a combination of Simvastatin and Ramipril increased lifespan in male C3B6F1 mice [30]. The combination of Atorvastatin with Telmisartan (referred to as ‘Atortel’) was chosen instead of Simvastatin/Ramipril because both stimulate PPARγ [31, 32].

Methotrexate (Meth) is a folate analog metabolic inhibitor with antineoplastic and immunosuppressive activities. Down-regulation of the enzyme dihydrofolate reductase, the methotrexate target, extends the lifespan of worms [33].

Methods

Mice and husbandry

The study used UM-HET3 mice, the progeny of CByB6F1 mothers (JAX stock 100,009), and C3D2F1 fathers (JAX stock 100,004). Mice from second and subsequent litters, produced over a 6-month interval at each site, were weaned into cages containing 3 males or 4 females. Approximately equal numbers of mice were weaned at each of the three test sites: the Jackson Laboratory (TJL), the University of Michigan (UM), and the University of Texas Health Science Center at San Antonio (UT). Table 3 shows the doses and starting ages of drugs tested using mice born in 2022, the “C2022 cohort”.

Table 3.

Compound dose and starting times

Group Compound Target
Dose
(ppm)
Achieved Dose
(ppm)
Start (months)
Males
AKG_early Alpha-ketoglutarate 20,000 3,262 7
Asta_low Astaxanthin 800 880 11
Asta_late Astaxanthin 800 880 16
Atortel Atorvastatin/Telmisartan 120/30 48/27 7
M160_late Mitoglitazone 300 126 18
Mec_ high Meclizine 2400 1,727 16
Mec_late Meclizine 800 68 16
Meth Methotrexate 0.2 0.3 14
Mife Mifeprestone 30 30 7
Pio Pioglitazone 100 94 7
Pio_late Pioglitazone 100 94 20
Females
AKG_early Alpha-ketoglutarate 20,000 3,262 7
Asta_ low Astaxanthin 800 880 11
Atortel Atorvastatin/Telmisartan 120/30 48/27 7
M160_late Mitoglitazone 300 126 18
Mec_ high Meclizine 2400 1,727 16
Meth Methotrexate 0.2 0.3 14
Mife Mifeprestone 30 30 7
Pio Pioglitazone 100 94 7
Pio_late Pioglitazone 100 94 20

Each site used the same supplier for bedding, and food was prepared centrally and shipped simultaneously to all three sites, but each site used its own local water supply. Cages were inspected daily, and mice were weighed at 6, 12, 18, and 24 months of age. Mice found dead were noted, and mice judged to be near death, using a symptom checklist, were euthanized for humane reasons and considered for statistical purposes as having died on the date of euthanasia. Mice that were removed from the study because of fighting or for reasons unrelated to aging and disease (examples: chip failure, water bottle leakage, escape) were considered alive at the time of removal and lost to follow-up thereafter. These “removed” mice are included in the Kaplan–Meier survival statistics but not in estimates of median or 90th percentile survival. “Removed” mice made up 4.1% of all males and 0.7% of females. All the experiments were approved by the respective animal care committees at each of the three sites.

Assessment of drug concentrations in food and tissue

These are given in the Supplementary Information

Statistical analyses

These are unchanged from previous ITP papers. The primary hypothesis of drug effectiveness was tested by a log-rank test stratified by site and tested separately for each sex. P-values presented are nominal, i.e., they are not adjusted for multiple comparisons, and readers should evaluate the evidence for our conclusions with this in mind. An important secondary hypothesis for each drug is that the drug increases the proportion of mice still alive at the 90th percentile age of the joint survival distribution combining control mice and those treated with the tested drug. This is the Wang-Allison (“WA”) test [34], using the Fisher Exact test version, and is taken as a surrogate for drug effects on maximum lifespan or, more accurately, on survival to exceptionally old ages. Statistical tables show median and p90 (90th percentile age), as well as p-values for log-rank and WA tests.

Analysis of drug effects on body weight was done by one-way ANOVA, separately for each sex at each age. When the ANOVA F-test statistic implied (at p < 0.05) that not all groups were the same in weight, a Sidak post-hoc test was used to evaluate all pairwise tests among groups, and the graphic shows only differences between a drug and the sex-matched control group at the same age.

Data sharing

All data is available through the Mouse Phenome Database, https://phenome.jax.org/projects/ITP1.

Results

C2022 interventions do not produce lifespan differences in males

None of the new compounds (Mife, Atortel, Meth, Pio) showed a significant increase in lifespan in males when data from all three sites were pooled (Table 1). AKG had previously been tested starting at 18 months and did not show an effect [25]. In C2022 we tested AKG starting at 7 months and did not see an effect with this earlier start either. Asta increased lifespan in a previous study when starting at 12 months at a target dose of 4000 ppm [10]. However, both starting at 11 months at 880 ppm and starting at 16 months at 880 ppm did not show an effect (Asta_Low). M160 showed an increase of 9% when starting at 7 months in a previous study [15] while starting at 18 months in the current study does not show an effect. Finally, Meclizine increased lifespan starting at 12 months at an achieved dose of 68 ppm previously [10] but starting at 16 months with 68 ppm (Mec_late) and with 1,727 ppm (Mec_High) did not show an effect. Pooled summary statistics is given in Table 1 and summary statistics for each site are given in Table S2.

Table 1.

Pooled Life Table Statistics for Mice from All Three Test Sites

Group n Median %Change Median Log-rank p90 %Change p90 Wang-Allison
Males
Control 300 813 1107
AKG_early 153 841 3.44 0.429 1108 0.09 1.000
Asta_low 210 843 3.69 0.214 1135 2.53 0.401
Asta_late 102 831 2.21 0.377 1075 −2.89 0.111
Atortel 153 847 4.18 0.644 1069 −3.43 0.253
M160_late 153 876 7.75 0.176 1106 −0.09 0.868
Mec_high 154 888 9.23 0.396 1119 1.08 0.413
Mec_late 153 800 −1.66 0.557 1073 −3.07 0.009
Meth 153 845 3.87 0.905 1062 −4.07 0.242
Mife 150 809 −0.49 0.464 1085 −1.99 0.402
Pio 156 858 5.54 0.172 1131 2.17 0.869
Pio_late 159 859 5.66 0.763 1080 −2.44 0.508
Females
Control 272 903 1128
AKG_early 132 889 −1.61 0.228 1083 −3.99 0.106
Asta_low 132 875 −3.16 0.021 1059 −6.12 0.012
Atortel 132 869 −3.82 0.154 1095 −2.93 0.468
M160_late 132 851 −5.76 0.001 1040 −7.80 0.006
Mec_ high 132 895 −0.94 0.327 1105 −2.04 0.468
Meth 132 902 −0.11 0.296 1096 −2.84 0.468
Mife 132 870 −3.65 0.099 1070 −5.14 0.468
Pio 132 818 −9.41  <.0001 1054 −6.56 0.012
Pio_late 130 863 −4.43 0.117 1114 −1.24 0.469

Body weights were measured at 6-month intervals for all animals. Males on Pio (starting at 7 months) were significantly heavier at 12, 18, and 24 months compared to controls (Fig. 1A). A similar effect was observed with M160 in C2021 [15]. Both Pio and M160 are members of the PPARγ-sparing thiazolidinedione family. Males that started on Pio at 20 months (Pio_late) did not differ in weight from control animals at the 24-month time point. Both Mec interventions (68 ppm and 1,727 ppm) were started at 16 months. Weight differences in males given 2400 ppm were significant by 18 months, with lower body weight compared to the controls. This effect increased at 24 months of age. Males on 800 ppm Mec were similar to the controls at these time points.

Fig. 1.

Fig. 1

Average bodyweights for intervention groups that were significantly different compared to the control animals. (A) Males, (B) Females

TJL female control mice show an unusually long lifespan

Comparison of survival statistics in a given year to results in earlier years (17 cohorts from C2004 to C2021) allows us to look for unusual aspects of each year’s survival outcomes. As shown in Fig. 2, the survival of control females appeared to be unusually long, at TJL only, compared to previous cohorts. The Z-score, calculated as the number of standard deviations by which a given statistic (in this case the median survival of control females) differs from that of a series of prior measurements, tests whether survival in a specific year differs significantly from that of prior years. TJL control females in C2022 were 3.13 standard deviations (i.e. Z = 3.13, two-tailed p = 0.0017) above the mean survival median in the C2004 – C2021 cohorts. For comparison Z scores for females were −1.5 for UM and −0.4 for UT, and Z scores for control males at TJL, UM, and UT were respectively 0.25, −0.49, and 0.9 (all non-significant). We concluded that the median survival of control females at TJL in C2022 was indeed unusually high, as suggested by the data in Fig. 2. We therefore conducted two analyses of drug effects on female mice, one in which all three sites were considered, and one in which only UM and UT data were included.

Fig. 2.

Fig. 2

Median lifespan for female control animals across 18 cohorts shows a deviant lifespan in TJL females for C2022

M160 and Pio, and perhaps Asta, lead to shorter lifespan in females

None of the interventions produced an increase in lifespan in females, either for data pooled from all three sites nor when only UM and UT data were included (Table 1 and Table 2). In fact, when the data is pooled from the three sites, we observe a significantly negative impact on lifespan with Asta, M160_late, and Pio (Fig. 3). As the TJL control females had an unusually long lifespan, we repeated the analysis with only pooling the data from UM and UT and observe a significantly negative impact on lifespan in M160_late and Pio (Fig. 3).

Table 2.

Pooled Life Table Statistics for Female Mice from UM and UT sites

Group n Median %Change Median Log-rank p90 %Change p90 Wang-Allison
Females
Control 180 855 1086
AKG_early 88 902 5.44 0.955 1077 −0.83 0.520
Asta_low 88 851 −0.47 0.275 1066 −1.84 0.659
Atortel 88 866 1.23 0.708 1086 0.00 1.000
M160_late 88 849 −0.70 0.034 1016 −6.45 0.015
Mec_ high 88 895 4.62 0.510 1123 3.41 0.654
Meth 88 886 3.63 0.894 1075 −1.01 1.000
Mife 88 865 1.11 0.347 1057 −2.67 0.659
Pio 88 802 −6.20 0.004 1044 −3.87 0.183
Pio_late 86 841 −1.64 0.281 1041 −4.14 0.185

Fig. 3.

Fig. 3

Kaplan–Meier survival plots for Asta_ low, M160_late, and Pio in females when calculated across all three sites and when calculated excluding TJL

Females on the Asta, Atortel, and Mec interventions had significantly lower weights compared to controls (Fig. 1B) with this difference showing for Atortel already showing at 12 months and for Asta and Mec (which started at 16 months) at 18 months of age. Unlike the males, females on Pio did not differ from control animals.

Discussion

In ITP Cohort 2022, no new compounds (Mife, Atortel, Meth, and Pio) showed a significant increase in lifespan, while Pio decreased lifespan in the females (−6.2%, P = 0.0047) when starting at 7 months of age.

We had tested alpha-ketoglutarate (AKG) in a previous study in which the drug was initiated at 18 months to mimic the design of an earlier published study with C57BL/6 J mice [24] and found that AKG had no significant effect in either sex using UM-HET3 mice [25]). We reasoned that perhaps this time point had been too late to have any beneficial effect, and we therefore repeated the study, using the same dose, but this time starting the intervention at 7 months. Again, we did not observe any effect of AKG in either males or females.

In a previous ITP study, Asta had increased lifespan in males (12%, P = 0.003) when starting at 12 months at a target dose of 4,000 ppm [10]. Given this result, we wanted to test whether there would be a similar or perhaps greater effect when giving a lower dose (880 ppm) but starting at 7 months and test whether starting later (16 months instead of 12 months) would still have a life extending effect. However, neither intervention led to significantly increased lifespan in either the males or females.

M160 had led to a lifespan increase of 9% (P = 0.015) in males when started at 7 months in our previous cohort (C2021) [15]. However, starting at 18 months did not lead to an increase. Interestingly, M160 significantly reduced lifespan in females (median: −0.7%, P = 0.0374; p90: −6.45%, P = 0.0238) as did pioglitazone (median: −6.2%, P = 0.0047). M160 is a structural analog and derivative of pioglitazone. They both act as PPARγ mediated insulin sensitizers but have PPARγ independent actions that differ between the two compounds. The basis for possible sex-specific harmful effects for these two drugs is not clear.

In a previous ITP study, Mec increased lifespan (8%, P = 0.03) in males, when started at 12 months at 800 ppm in C2019 [10]. Because Mec is an mTORC1 inhibitor, and because late intervention with the mTOR inhibitor Rapamycin increases lifespan [35], we reasoned that Mec might also increase lifespan if started at a later age in males, or if it was supplied at a higher dose (1,727 ppm) to males or females. Neither intervention produced a significant lifespan extension in the current study.

We carefully looked for a possible explanation for the unusually long median lifespan of the TJL C2022 control females. These animals were in the same room, getting the same water and bedding as all other groups in this study, as well as overlapping with the C2021 and C2023 control females and getting the same diet as animals from these groups. The C2023 control females are far enough along to see that their median lifespan is in line with previous cohorts (data not shown) and that the C2022 control females are an outlier with no obvious explanation.

In summary, none of the 11 interventions in the C2022 cohort, which included several compounds (M160, Mec, and Asta) that had previously shown an effect at a different dose or starting age, showed an increase in lifespan in males or females. It is possible that for these compounds, intervention in a specific dose and age window is required. Their previously published increases in median lifespan (9%, 8%, and 12%, respectively) were at or near the lower level of what is expected to be able to discover at 80% power, and none of them showed a change in the Wang-Allison statistic. Furthermore, the p-values are nominal, and chance effects can be expected in any series of studies for truly ineffective agents.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

We thank technicians at all three sites for excellent care, breeding and husbandry of the mice, as well as for collecting lifespan, health and weight measurements. At TJL this work was done by Nelson Durgin, Vicki Ingalls, Pam Krason, and Leonor Robidoux. At UM the work was done by Jacob Sheets, Lori Roberts, Micah Bush, Robert Dilg, and Lindsey Burger. And at UT the work was done by Isabella Arredondo, Vivian Cerritos, Kassandra Gonzalez, Matthew Hernandez, Oscar Hernandez, Sophia Kurtz, Briana Oldham, William Thomson and Cassandra Tolento.

Author contributions

RS, RAM and DEH were the principal investigators at the three collaborating institutions at the start of the C2022 project, and are responsible for project design, supervision of technical personnel and interpretation of results. RK replaced Dr. Harrison as PI at TJL in 2024. RK was responsible for manuscript preparation, with assistance from the other PIs. PCR supervised animal laboratory personnel and data collection at TJL. EF and VD supervised animal laboratory personnel and data collection at UT. MAJ, BG and MLC supervised analytical pharmacology studies at UT. MH was responsible for specimen collection and archiving. RAM, JG, AG, NK and NJ assisted with data analysis.

Funding

This work was funded in part by NIA grants AG022308 (RK), AG022303 (RAM), AG066346 (MB), AG022307 and AG013319 (RS), with important facilities supported by CA034196 (TJL) and AG024824 (UM). RS is supported by a Senior Research Career Scientist Award from the Department of Veterans Affairs Office of Research and Development.

Data Availability

The data that support the findings of this study are available at The Jackson Laboratory Mouse Phenome Database at https://phenome.jax.org/search?searchterm=ITP.

Declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Higuera-Ciapara I, Félix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185–96. [DOI] [PubMed] [Google Scholar]
  • 2.Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications–a review. Mar Drugs. 2014;12(1):128–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Nrf2 a molecular therapeutic target for astaxanthin. Biomed Pharmacother. 2021;137:111374. [DOI] [PubMed] [Google Scholar]
  • 4.Kidd P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern Med Rev. 2011;16(4):355–64. [PubMed] [Google Scholar]
  • 5.Fakhri S, Abbaszadeh F, Dargahi L, Jorjani M. Astaxanthin: a mechanistic review on its biological activities and health benefits. Pharmacol Res. 2018;136:1–20. [DOI] [PubMed] [Google Scholar]
  • 6.Salamone MC, et al. Analysis of CD1 molecules on haematological malignancies of myeloid and lymphoid origin. I. Cell surface antigen expression. Dis Markers. 1990;8(5):265–74. [PubMed]
  • 7.Goto S, et al. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta. 2001;1512(2):251–8. [DOI] [PubMed] [Google Scholar]
  • 8.Kim SH, Kim H. Inhibitory effect of astaxanthin on oxidative stress-induced mitochondrial dysfunction-a mini-review. Nutrients. 2018. 10.3390/nu10091137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nishida Y, Nawaz A, Hecht K, Tobe K. Astaxanthin as a novel mitochondrial regulator: A new aspect of carotenoids, beyond antioxidants. Nutrients. 2021;14(1):107. [DOI] [PMC free article] [PubMed]
  • 10.Harrison DE, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. Geroscience. 2024;46(1):795–816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wibble T, Engström J, Verrecchia L, Pansell T. The effects of meclizine on motion sickness revisited. Br J Clin Pharmacol. 2020;86(8):1510–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Allen SA, Tomilov A, Cortopassi GA. Small molecules bind human mTOR protein and inhibit mTORC1 specifically. Biochem Pharmacol. 2018;155:298–304. [DOI] [PubMed] [Google Scholar]
  • 13.Colca JR, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. Diabetes Obes Metab. 2014;16(11):1048–54. [DOI] [PubMed] [Google Scholar]
  • 14.Colca JR, Tanis SP, Kletzien RF, Finck BN. Insulin sensitizers in 2023: lessons learned and new avenues for investigation. Expert Opin Investig Drugs. 2023;32(9):803–11. [DOI] [PubMed] [Google Scholar]
  • 15.Strong R, et al. Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice. Geroscience. 2025. 10.1007/s11357-025-01881-6. Online ahead of print. [DOI] [PMC free article] [PubMed]
  • 16.Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 2005;66(1):150–61. [DOI] [PubMed] [Google Scholar]
  • 17.Waugh J, et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85–109. [DOI] [PubMed] [Google Scholar]
  • 18.Ledwidge R, Blanchard JS. The dual biosynthetic capability of N-acetylornithine aminotransferase in arginine and lysine biosynthesis. Biochemistry. 1999;38(10):3019–24. [DOI] [PubMed] [Google Scholar]
  • 19.Ott P, Clemmesen O, Larsen FS. Cerebral metabolic disturbances in the brain during acute liver failure: from hyperammonemia to energy failure and proteolysis. Neurochem Int. 2005;47(1–2):13–8. [DOI] [PubMed] [Google Scholar]
  • 20.Long LH, Halliwell B. Artefacts in cell culture: α-ketoglutarate can scavenge hydrogen peroxide generated by ascorbate and epigallocatechin gallate in cell culture media. Biochem Biophys Res Commun. 2011;406(1):20–4. [DOI] [PubMed] [Google Scholar]
  • 21.Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chin RM, et al. The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014;510(7505):397–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Su Y, et al. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging Albany NY. 2019;11(12):4183–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Asadi Shahmirzadi A, et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metab. 2020;32(3):447-456.e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Miller RA, et al. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. Geroscience. 2024;46(5):4657–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tower J, et al. Mifepristone/RU486 acts in Drosophila melanogaster females to counteract the life span-shortening and pro-inflammatory effects of male Sex Peptide. Biogerontology. 2017;18(3):413–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Landis GN, et al. The progesterone antagonist mifepristone/RU486 blocks the negative effect on life span caused by mating in female Drosophila. Aging (Albany NY). 2015;7(1):53–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Taylor AI, et al. Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes. Horm Metab Res. 2009;41(12):899–904. [DOI] [PubMed] [Google Scholar]
  • 29.Wang Y, et al. Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes. Diabetologia. 2011;54(2):440–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Spindler SR, Mote PL, Flegal JM. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. Age. 2016;38(5–6):379–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51(2):58–62. [DOI] [PubMed] [Google Scholar]
  • 32.Wang J, et al. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology. 2014;79:249–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Annibal A, et al. Regulation of the one carbon folate cycle as a shared metabolic signature of longevity. Nat Commun. 2021;12(1):3486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wang C, et al. Statistical methods for testing effects on “maximum lifespan.” Mech Ageing Dev. 2004;125(9):629–32. [DOI] [PubMed] [Google Scholar]
  • 35.Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The data that support the findings of this study are available at The Jackson Laboratory Mouse Phenome Database at https://phenome.jax.org/search?searchterm=ITP.


Articles from GeroScience are provided here courtesy of Springer

RESOURCES